Clinical trial assesses anti-melanoma vaccine's ability to induce an anti-cancer immune response
Cancer vaccines prime the immune system to attack cancer cells, decreasing tumor progression. IL-12p70, a molecule produced by certain types of immune cells, has been shown to reduce tumor progression, but delivering it as part of a cancer vaccine has been limited because of its toxicity in high doses. In the current issue of the Journal of Clinical Investigation, Dr. Beatriz Carreno and colleagues at Washington University report the results of a clinical trial that tested a vaccine to treat newly diagnosed advanced melanoma. A portion of each patient's own immune cells, ...